Please provide your email address to receive an email when new articles are posted on . Lenalidomide maintenance therapy significantly improved PFS compared with observation among patients with newly ...

Lenalidomide is a cornerstone therapy for multiple myeloma (MM) and other hematologic malignancies, but conventional oral dosing is limited by high peak plasma concentrations, rapid clearance, and ...

Data from a large phase III trial presented at the 2022 American Society of Hematology (ASH) annual meeting examined the relationship between minimal residual disease, progression-free survival, and ...

Phase I data presented at the 2023 American Society of Hematology (ASH) annual meeting showed the benefit of lenalidomide (Revlimid) rechallenge in relapsed/refractory multiple myeloma patients ...

The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Lenalidomide, an ...

As a precursor to myeloma, smoldering multiple myeloma (MM) currently has no treatment. In fact, the standard of care is observation until the patient starts to present with symptoms. However, ...

A new study by Mayo Clinic Researchers calls into question the current standard of care for treating smoldering multiple myeloma. The cancer drug lenalidomide can delay the symptoms of myeloma, ...

Lenalidomide has proven efficacy and safety and has been shown to reduce transfusion requirements and reverse cytogenetic abnormalities in lower-risk myelodysplastic syndromes (MDS). However, ...

REVLIMID® and rituximab (R2) has the potential to become a chemotherapy-free combination treatment option for patients with follicular lymphoma who have relapsed or did not respond to previous ...

Myelodysplastic syndromes (MDS) are characterized by defective hematopoiesis. The resultant anemia is difficult to treat and therapies based on erythropoietin and growth factors are often ineffectual ...

The recommended starting dosage of lenalidomide for the treatment of MM is 25 mg/day p.o. on days 1-21 of a 28-day cycle. On the basis of the trials previously presented, the recommended dosage of ...